Sweet Earth Holdings and Thoughtful Brands Inc. Sign Definitive Supply Agreement for Sweet Earth’s Organic CBD Dog Treats
Sweet Earth Holdings Corp. (CSE:SE) (FSE:1KZ1) (“Sweet Earth”) is pleased to announce that it has signed a Definitive Supply Agreement (the “Supply Agreement”) with Thoughtful Brands Inc. (“Thoughtful Brands”) to supply dog treats under Thoughtful Brands. On June 22, 2020 Sweet Earth announced a Letter of Intent with Mota Ventures Corp., which has subsequently changed its name to Thoughtful Brands Inc.
Under the Supply Agreement, Sweet Earth is to officially become Thoughtful Brands’ exclusive dog treat provider, which will be marketed and sold on under the brand name Nature’s Exclusive, a key line in Thoughtful Brand’s rapidly expanding global natural health products and ecommerce technology platform.
Thoughtful Brands selected Sweet Earth as its exclusive dog treat supplier because of Sweet Earth’s award-winning farm-to-shelf platform. The Supply Agreement was finalized after it became apparent that both parties are fully committed to providing high-quality certified organic canine treats at an affordable price.
Sweet Earth also maintains a portfolio of products that includes facial and body care, men’s, spa, hemp, and muscle products that are sold on its website, https://sweetearthskincare.com. The Supply Agreement marks the first time the Company will market products under a different brand. In addition to the parties’ mutual commitment to high-quality products, the Company was impressed with Thoughtful Brands’ newly formed Ecommerce Tech LLC, a subsidiary operating a powerful ecommerce software platform (recently acquired from Unified Funding’s Offer Space LLC).
“We are thrilled to be working with Sweet Earth, a renowned company whose sophisticated hemp-CBD offerings have long been celebrated,” said Thoughtful Brands, Inc. CEO, Ryan Dean Hoggan. “We are eager to propel the success of their CBD canine products by utilizing our global eCommerce platform and enhanced technology capabilities. We look forward to adding the brand to our portfolio and are hopeful for future collaborations.”
Sweet Earth canine products that will be sold under the Nature’s Exclusive brand include the popular Beef and Cheddar Potato CBD Dog Treats. Each organic treat is fortified with Vitamin E as a natural preservative.
According to Dogs Naturally1, research shows that CDB dog treats are effective dog supplements for:
- Arthritis and joint pain
- Digestive issue
- Neurological disorders (such as seizures and epilepsy)
- Blood disorders
Sweet Earth is a vertically integrated company that uses exclusively organic ingredients for all its products.
According to BDS Analytics and Arcview Group’s2 research, the pet CBD market is projected to grow five percent faster than the overall CBD market over the next four years, from $64 million in 2018 to $810 million in 2024.
Today’s Veterinary Business3, a leading publisher on animal health, states that U.S. pet treat market reached US$6.7 billion in 2019. Within the pet treat sector, CDB products proved to maintain the highest growth rate4. In addition, online sales of pet snacks have also rapidly grown from 0% to 13%. A catalyst of ecommerce’s rapid market expansion is attributed to the platform’s ability to educate consumers on products prior to purchase.
Peter Espig, CEO of Sweet Earth, commented, “We are very excited to work closely with Thoughtful Brands Inc., a company that we feel maintains the CBD industry’s premier ecommerce platform. Leveraging its powerful global platform and enhanced technological capabilities, we are confident that our dog treat business can expand rapidly. During our due diligence process, we were very impressed with our partner’s commitment to product quality, pricing and customer services, all qualities that are also important at Sweet Earth.”
About Sweet Earth
Sweet Earth is a vertically integrated “farm to shelf” hemp grower with a farm in Applegate, Oregon, that maintains a full line of hemp and CBD products for the US and global market. Its products combine CBD with herbal and organic ingredients, all of which are selected for their beneficial properties to soothe, rejuvenate, and reduce inflammation. In addition to high-end finished products, Sweet Earth prides itself on sustainability by minimizing the use of plastics in both production and packaging.
Sweet Earth’s in-house genetics team has been working on its own proprietary hemp strain. This strain has been grown in its indoor greenhouse resulting in high yielding CBD rich flower. Sweet Earth products are sold on its website: https://sweetearthskincare.com.
ON BEHALF OF THE BOARD
CEO / Director
For additional information contact:
Peter Espig / CEO and Director
Telephone: (778) 385-1213
Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
 Author Carol Dougal April 9, 2020: https://www.dogsnaturallymagazine.com/cbd-dog-treats-are-they-worth-the-money
 Arcview Group is a leading research focused on the hemp and cannabis industry.
 Today’s Veterinary Business is the first addition to the NAVC family of publications to focus on the business side of the animal health practice. With a dedication to leadership, innovation and success, Today’s Veterinary Business provides content that will inspire veterinary practice teams to elevate overall practice performance.
 Source: Author Jordan Tyler, Adobe Stock Oct. 11, 2019
Naturally Splendid Enterprises Ltd. (“Naturally Splendid”) (TSXV:NSP) (OTC:NSPDF) (Frankfurt:50N) is pleased to announce that it has closed its non-brokered private placement financing for a total of 15,887,503 units (the “Units”) at $0.06 per Unit, for total gross proceeds of $1,053,250 (the “Offering”). Due to oversubscribed demand, the private placement financing was increased from 14,166,667 Units to 17,554,167.
Each Unit consists of one common share of Naturally Splendid and one half of a common share purchase warrant (each a “Warrant”), with each Warrant entitling the holder to purchase one additional common share for a period of two years from the date of the issue at an exercise price of $0.10 per share. Naturally Splendid has the right to accelerate the expiry date of the Warrants if, at any time, the average closing price of Naturally Splendid’s common shares is equal to or greater than $0.15 for 10 consecutive trading days. In the event of acceleration, the expiry date will be accelerated to a date that is 30 days after Naturally Splendid issues a news release announcing that it has elected to exercise this acceleration right.
In connection with the initial tranche of financing, Naturally Splendid paid finders a cash commission totaling $7,432 and issued a total of 123,867 finder’s warrants. Each finder’s warrant has the same terms and conditions as the Warrants.
The securities issued under the financing will be subject to a hold period expiring on January 16, 2021 pursuant to applicable securities laws and the rules of the TSX Venture Exchange.
Proceeds of the Offering will be directed towards the recently announced joint venture with Biologic Pharmamedical Research (“Biologic”) for lab and office space in preparation for a phase 2 clinical trial for a potential COVID-19 treatment featuring the target drug CavaltinibTM, as well as towards the Company’s 100% owned Prosnack Natural Foods, Safe Quality Food Level 2 (SQF2) Certified food manufacturing facility. Additionally, funds will be used to pay outstanding management fees, retire corporate indebtedness and for general working capital purposes which will continue to support the food supply chain by manufacturing safe, nutritious, non-perishable bars and bites.
The name of the joint venture with Biologic is Plasm Pharmaceutical Inc. (“Plasm”). Plasm has been granted certain rights from Biologic’s patents as it relates to applications for treating COVID-19 infections. The categories to be licensed will include, but are not limited to COVID-19 applications, as well as additional respiratory indications that may arise out of the fast-tracked phase 2 clinical trial.
Previously, Naturally Splendid announced that Health Canada had issued a No Objection Letter for CavaltinibTM, the target drug, in response to the Clinical Trial Application as prepared by Biologic. The Company awaits further direction from Health Canada.
Biologic CEO Mr. Franco Cavaleri states, “In addition to pursing a COVID-19 treatment, there is optimism that the trial and the ensuing bench work will help expand the indications for Cavaltinib(TM) to respiratory conditions such as asthma and COPD; and reveal mechanisms of activity that justify the results we’ve seen in cases of autoimmune diseases like colitis, crohn’s and rheumatoid arthritis. We have been working with Naturally Splendid for over two years and are excited to expand this relationship through the Plasm joint venture.”
Plasm’s website has been launched and can be found at: www.plasmpharma.com
Company CEO Mr. J. Craig Goodwin states, “While pursuing the COVID-19 treatment clinical trial, the company continues its role in the food supply chain manufacturing plant-based bars and bites. Food facilities with certifications such as our Safe Quality Food designation have never been more valuable and the demand for plant-based foods, have never been higher. It’s worth noting that even CavaltinibTM the target drug for our COVID-19 clinical trial is originated from plants. The Company continues to seek opportunities to expand our plant-based offerings and look forward to updates in the near future. The plant-based food category is growing at a rate outpacing traditional food channels and we expect this trend to continue post pandemic times and we will continue to position the Company to participate in this rapidly growing category.”
About Naturally Splendid Enterprises Ltd.
NSE operates a Safe Quality Food Level 2 certified food manufacturing facility just outside Vancouver, BC in Canada. We have established numerous healthy, functional foods under recognized brands such as Natera Sport(TM), Natera Hemp Foods, CHII (TM), Elevate Me(TM) and Woods Wild Bar. The Company has a myriad of new products and line extensions under development that are approaching launch. NSE has also developed proprietary technologies for the extraction of high demand, healthy omega 3 and 6 oils from hemp. NSE is the current “go-to” manufacturer for healthy, functional food products and ingredients focusing on plant-based ingredients. The Company provides contract manufacturing services for many global healthy food companies, private labelling a wide variety of nutritional food products destined for global healthy food markets.
For more information e-mail email@example.com or call Investor Relations at 604-673-9573
On Behalf of the Board of Directors
Mr. J. Craig Goodwin
Naturally Splendid Enterprises Ltd.
(NSP – TSX Venture; NSPDF – OTCQB; 50N Frankfurt)
#108-19100 Airport Way
Pitt Meadows, BC, V3Y 0E2
Office: (604) 465-0548
Fax: (604) 465-1128
Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. Naturally Splendid cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond Naturally Splendid’s control including, Naturally Splendid’s ability to compete with large food and beverage companies; sales of any potential products developed will be profitable; sales of shelled hemp seed will continue at existing rates or increase; the ability to complete the sales of all bulk hemp seed purchase orders; and the risk that any of the potential applications may not receive all required regulatory or legal approval. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, Naturally Splendid undertakes no obligation to publicly update or revise forward-looking information.
NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
GreenStar Biosciences (CSE:GSTR, OTC Pink:GTSIF) is a company focused on growth-oriented technologies with its core interest in transformational medicines and wellness. In particular, the company is targeting the psychedelic market in large part thanks to acquisitions and development of assets, products and technologies.
Within the psychedelics space, GreenStar Biosciences stands out from its competitors because it has physicians as part of its management team and four provisional patents filed for medicines that the company believes will have true efficacy in treating certain conditions.
Additionally, GreenStar Biosciences is forming a scientific advisory board that will focus largely on the psychedelics space because it is committed to the product basis and the types of medicine the company is developing.
GreenStar Biosciences’ company highlights include the following:
- Is focused primarily in the US market for head trauma
- Currently targeting the psychedelics market through its acquisition of Eleusian Biosciences
- Therapeutic areas the company is focused on include brain trauma and posttraumatic stress disorder (PTSD) associated with head trauma
- Through the acquisition, GreenStar Biosciences acquired provisional patents to treat PTSD or mTBI with PTSD
- A third provisional patent was also acquired for methods and compositions for treating mTBI PTSD alone with 3,4 MDMA plus NAC
- Its fourth patent pending is a medical device for delivery of medicines to the olfactory bulb and GreenStar is currently searching for a device development partner.
- Eleusian is collaborating with a multidisciplinary team of scientists and physicians from the University of Miami to develop therapeutics to treat mTBI with PTSD or PTSD alone based on the combination of psilocybin and NAC
- Through its subsidiary Cowlitz County Cannabis Cultivation Inc., GreenStar Biosciences owns certain assets including the property leases and intellectual property of Cowlitz
- Cowlitz is one of the top 5 Tier 2 processors in Washington state and has its products broadly available at dispensaries across the state
Codebase Ventures Inc. (“Codebase” or the “Company”) (CSE:CODE)(FSE:C5B)(OTCQB:BKLLF) announces that World High Life Plc, (AQSE LIFE) (OTCQB:WRHLF), in which the Company has invested, has announced that brand ambassador Georges St-Pierre will be showcased on BT Sport, one of Europe’s largest sport networks and rights holder for UFC (Ultimate Fighting Championships) in the U.K.
Georges “Rush” St-Pierre, also known as “GSP,” is a Canadian professional mixed martial artist and 3-time UFC world champion who holds black belts in both Kyokushin karate and Brazilian Jiu Jitsu. As Brand Ambassador, Mr. St-Pierre facilitates and provides promotional services, including branding, social media, product placement, endorsement and overall support of the World High Life and the Love Hemp brand.
This showcase special on BT Sport will serve to provide a retrospective on Georges’ incredible history in the UFC and provide significant exposure for the Love Hemp brand, a World High Life wholly owned subsidiary.
Georges St-Pierre BT Sport Programme Highlights
- Georges St-Pierre BT Sport Special will consist of a 5-hour programme, to air on Thursday, August 27th from 9pm to 1am in the UK
- The special will consist of a 1-hour interview with Georges wearing Love Hemp branded apparel
- The special will include 4 hours of insights from Georges as his favourite fights are showcased
Georges retired from the sport on 13 December 2013, holding the UFC record for most wins in title bouts and then returned to the octagon after a four-year layoff, on 4 November 2017 at UFC 217 in New York City (Madison Square Garden), where he defeated Michael Bisping by submission in the third round to win the UFC Middleweight Championship title, becoming the fourth fighter in the history of the organization to be a multi-division champion. On 7 December 2017, after being diagnosed with ulcerative colitis, Georges vacated his UFC middleweight title and officially announced his retirement from professional MMA competition on 21 February 2019.
In the World High Life announcement, Mr. St-Pierre noted: “I believe that using Love Hemp’s CBD products in my training helped my recovery and overall wellbeing greatly, and I embrace this opportunity to help create innovative products and grow the Love Hemp brand so that others can benefit as well. I am committed to building great teams and getting world class results in everything I do, and I am thrilled to contribute to the World High Life and Love Hemp team to help achieve those standards.”
About Codebase Ventures Inc.
Codebase Ventures Inc. is an investment company, led by technology and business experts who invest early in great ideas in sectors that have significant upside, including the cannabis sector. We operate from the understanding that technology is always evolving, bringing early opportunities for strategic investments that can deliver the exponential returns to our shareholders. We seek out and empower the innovators who are building tomorrow’s standards with platforms, protocols and innovations – not just products. We invest early, support those founders, take their ideas to market, and work tirelessly to help them realize their vision.
For further information, please contact:
George Tsafalas – Ivy Lu
Telephone: Toll-Free (877) 806-CODE (2633) or 1 (778) 806-5150
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward Looking Statements
Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. All statements other than statements of historical fact are forward-looking statements, including, without limitation, statements regarding future financial position, business strategy, use of proceeds, corporate vision, proposed acquisitions, partnerships, joint-ventures and strategic alliances and co-operations, budgets, cost and plans and objectives of or involving the Company. Such forward-looking information reflects management’s current beliefs and is based on information currently available to management. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “predicts”, “intends”, “targets”, “aims”, “anticipates” or “believes” or variations (including negative variations) of such words and phrases or may be identified by statements to the effect that certain actions “may”, “could”, “should”, “would”, “might” or “will” be taken, occur or be achieved. A number of known and unknown risks, uncertainties and other factors may cause the actual results or performance to materially differ from any future results or performance expressed or implied by the forward-looking information. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Company including, but not limited to, the impact of general economic conditions, industry conditions and dependence upon regulatory approvals. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company does not assume any obligation to update or revise its forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by securities laws.
Cardiol Therapeutics Inc. (TSX:CRDL) (OTCQX:CRTPF) (“Cardiol” or the “Company”), a leader in the development of pharmaceutical cannabidiol formulations for the treatment of cardiovascular diseases, including heart failure and acute myocarditis, is pleased to announce the initiation of its Health Canada approved Phase 1 clinical study of CardiolRx™. CardiolRx is an extra strength formulation of pharmaceutical cannabidiol that has been formulated to set the highest industry standard for purity, consistency, and stability.
Cardiol’s Phase 1 clinical trial is a double-blind, placebo-controlled, randomized study to assess safety, tolerability, and pharmacokinetics of single followed by multiple day ascending doses of CardiolRx administered orally in up to 55 healthy adult subjects, both in the fasting and fed states. The study is expected to be completed during Q4, 2020, and is believed to represent the first Health Canada approved study of a high concentration (100 mg/mL) cannabidiol formulation that contains virtually no THC (<5 ppm). This level of purity is extremely important for patient populations who should not take THC, particularly children, where THC can impact brain development, and older individuals who wish to avoid intoxication and who may be more susceptible to adverse drug effects.
By measuring standard safety parameters and the pharmacokinetics of CardiolRx, including the degree of drug absorption and resulting blood levels at escalating doses, the Phase 1 study will provide important information to optimize dosing levels for the Company’s planned Phase 2 international trial in acute myocarditis. Cardiol’s acute myocarditis trial has been designed by an independent steering committee comprising highly distinguished thought leaders in heart failure and myocarditis from international centers of excellence, including: the Cleveland Clinic, the Mayo Clinic, the Houston Methodist DeBakey Heart and Vascular Center, the University of Ottawa Heart Institute, McGill University Health Centre, University of Pittsburgh Medical Center, and Charité Hospital Berlin.
Acute myocarditis is an inflammatory condition of the heart that represents a leading cause of sudden cardiac death in children and otherwise healthy young adults. The most common cause of acute myocarditis is a viral infection of the heart tissue which is initially responsible for the inflammation. Based on the large body of experimental evidence of the anti-inflammatory and cardioprotective properties of cannabidiol in models of cardiovascular disease, the Company believes there is an opportunity to develop a potential breakthrough therapy for acute myocarditis that would be eligible for designation as an orphan drug. The U.S. orphan drug program was created to offer companies significant incentives, including multi-year marketing exclusivity, to develop treatments for diseases that affect fewer than 200,000 people in the U.S. The program was successfully utilized to accelerate the first FDA approval of cannabidiol for the treatment of two pediatric epilepsy syndromes as orphan diseases. Cardiol believes there is a similar opportunity to fast track the development of its CardiolRx formulation as an orphan drug for the treatment of acute myocarditis, for which there is currently no accepted standard of care.
“There is now increasing evidence that the SARS-CoV-2 virus (responsible for COVID-19) is causing a disturbing number of new cases of myocarditis in young adults, perhaps most notably Red Sox pitcher Eduardo Rodriguez and several U.S. college football players. As global awareness of the devastating consequences of acute myocarditis increases in the wake of the COVID-19 pandemic, we see an opportunity to accelerate the development of CardiolRx as an important new cardioprotective therapy,” said David Elsley President and CEO of Cardiol Therapeutics Inc. “The initiation of our Phase 1 clinical study represents another significant milestone for Cardiol, as we aim to position the Company at the forefront of heart failure research.”
About Cardiol Therapeutics
Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) is a leader in the development of pharmaceutical cannabidiol formulations for the treatment of cardiovascular diseases, including heart failure and acute myocarditis. The Company’s lead product, CardiolRx™, is pharmaceutically produced, manufactured under cGMP, and is THC free (<5 ppm). The Company plans to commercialize CardiolRx in the billion-dollar market for medicinal cannabinoids in Canada.
Cardiol is planning a Phase 2 international trial of CardiolRx in acute myocarditis, a condition caused by inflammation in heart tissue, which remains the most common cause of sudden cardiac death in people less than 35 years of age. The Company is also developing proprietary cannabidiol formulations for the treatment of inflammation in the heart that is associated with the development and progression of heart failure. Heart failure is the leading cause of death and hospitalization in North America, with associated annual healthcare costs in the U.S. alone exceeding $30 billion. For further information about Cardiol Therapeutics, please visit cardiolrx.com.
For further information, please contact:
David Elsley, President & CEO +1-289-910-0850
Trevor Burns, Investor Relations +1-289-910-0855
Cautionary statement regarding forward-looking information:
This news release contains “forward-looking information” within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, that address activities, events, or developments that Cardiol Therapeutics Inc. (“Cardiol” or the “Company”) believes, expects, or anticipates will, may, could or might occur in the future are “forward- looking information”. Forward-looking information contained herein may include, but is not limited to, statements with respect to the expected completion of the Phase 1 clinical study in Q4, 2020 and the Company’s plans to commercialize CardiolRx and for an international clinical study of CardiolRx. Forward-looking information contained herein reflects the current expectations or beliefs of Cardiol based on information currently available to it and is subject to a variety of known and unknown risks and uncertainties and other factors that could cause the actual events or results to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information. These risks and uncertainties and other factors include that the risks and uncertainties associated with product commercialization and clinical studies referred to in the Company’s Annual Information Form dated March 30, 2020. These risks, uncertainties and other factors should be considered carefully, and investors should not place undue reliance on the forward-looking information. Any forward-looking information speaks only as of the date on which it is made and, except as may be required by applicable securities laws, Cardiol disclaims any intent or obligation to update or revise such forward-looking information, whether as a result of new information, future events or results or otherwise. Although Cardiol believes that the expectations reflected in the forward-looking information are reasonable, they do involve certain assumptions, risks, and uncertainties and are not (and should not be considered to be) guarantees of future performance. It is important that each person reviewing this news release understands the significant risks attendant to the operations of Cardiol.
- MustGrow has confirmed disease control of Clubroot resting spores in greenhouse soil tests.
- Outstanding Efficacy: 96.1% control at 0.5 gal/acre and 98.5% control at 10 gal/acre.
- Clubroot is a devastating soil-borne disease-causing canola crop loss with no effective treatment options currently available.
MustGrow Biologics Corp. (CSE:MGRO) (OTCQB:MGROF) (FSE:0C0) (the “Company”, “MustGrow”) is pleased to announce successful greenhouse soil test results of its patented mustard-derived bio-pesticide on clubroot resting spores (Plasmodiophora brassicae) (“Clubroot”). With successful greenhouse soil efficacy, MustGrow will advance to larger scale Clubroot field tests in 2021. Study results and applicability are patent-protected under MustGrow’s existing suite of issued patents.
- 96.1% disease control at 0.5 gal/acre application rate
- 96.5% disease control at 2.5 gal/acre application rate
- 98.5% disease control at 10 gal/acre application rate
Clubroot is a rapidly-spreading disease pathogen destroying canola, one of Canada’s more profitable crops with over 20 million acres grown annually. Industry experts conservatively estimate C$500 million in annual canola crop losses in Canada caused by Clubroot. Current measures cannot eradicate Clubroot completely – they are only intended to slow down the spread and reduce the incidence and severity of the disease. Some field infections may lead to 100% crop loss.
Greenhouse Soil Study: Remarkable Disease Control at Low Applications
Utilizing MustGrow’s signature mustard-derived liquid bio-pesticide TerraMGTM, through an independent third-party testing facility, Discovery Seed Labs Ltd., MustGrow has confirmed disease control of Clubroot at 5 different application rates: 10 gal/acre, 5 gal/acre, 2.5 gal/acre, 1 gal/acre, and 0.5 gal/acre. The application rates were calculated based on the weight of the top 6.7 inches of soil in one acre. Planting occurred 7 days after soil treatment; then roots were assessed 7 weeks after planting.
All of MustGrow’s treatment application rates showed a significant “control” reduction in the amount of Clubroot present in the root material at the conclusion of the experiment. The greatest reduction was seen in the 10 gal/acre application rate which had a 98.5% reduction of spores compared to the non-treated sample. Of particular significance, 96.1% disease control was measured at the exceptionally low application rate of 0.5 gal/acre.
“It is great to see that TerraMG continued to perform in the latest round of tests. With this new data we now plan on continuing the Clubroot work to the final field testing stage to potentially provide a valuable crop-protection tool for farmers,” remarked Colin Bletsky, COO of MustGrow. “I am very hopeful that we can potentially have a key piece of the package to help growers manage this disease.”
In June 2020, MustGrow reported 100% control of Clubroot spores in a laboratory setting. MustGrow’s crop protection technology has consistently demonstrated efficacious benefits similar to chemistry-based “chemical” products without the harmful safety profile often associated with these chemical products. The need for bio-pesticides is increasing as farmers, consumers and regulators seek ‘natural biological’ alternatives to synthetic chemical pesticides.
Clubroot: Devastating Canada’s Canola Crop (1)(2)
Clubroot is a serious soil-borne disease caused by a fungus called Plasmodiophora brassicae. Swellings or galls form on the roots of canola plants, which may ultimately cause premature death of the plant. Once a field is infested, there are no economical control measures currently available that can eradicate Clubroot, with some field infections leading to 100% crop loss. Since 2003, thousands of infested fields have been identified across canola growing regions in Canada.
Alarmingly, some resistant Clubroot varieties with high spore-loads are heavily infesting canola fields. The endemic disease is also spreading to areas of Canada where Clubroot has not historically been an issue because the spores travel so easily – transmitting through soil and trash for example. This is especially problematic for vehicles moving between field properties, including oil production equipment, farming machinery, vehicles, etc.
Many farmers are taking serious precautionary measures, including lengthening crop rotations, seeking Clubroot-resistant varieties, and cleaning soil off between fields – all proactive techniques inversely impacting crop economics. Current measures cannot eradicate Clubroot completely; they are only intended to slow down the spread and reduce the incidence and severity of the disease. Practical, economic and effective solutions for large scale canola crops are still being investigated.
(1) Source: www.albertafarmexpress.ca
(2) Source: www.canolacouncil.org
MustGrow is a publicly traded (CSE: MGRO) (OTCQB: MGROF) (FSE: 0C0) agriculture biotech company focused on providing natural science-based biological solutions for high value crops, including fruits & vegetables. MustGrow has designed and owns a United States EPA-approved natural solution that uses the mustard seed’s natural defence mechanism to protect plants from pests and diseases. Over 110 independent tests have been completed, validating MustGrow’s safe and effective signature products. The product, in granule format, is EPA-approved across all key U.S. states and by Health Canada’s PMRA (Pest Management Regulatory Agency) as a bio-pesticide for high value crops such as in fruit & vegetables. MustGrow has now concentrated a liquid format which it’s calling TerraMG, and with regulatory approval, could be applied through standard drip or spray equipment, improving functionality and performance features.
The Company has approximately 37 million basic common shares issued and outstanding. For further details please visit www.mustgrow.ca.
ON BEHALF OF THE BOARD
Director & CEO
Certain statements included in this press release constitute “forward-looking statements” which involve known and unknown risks, uncertainties and other factors that may affect the results, performance or achievements of MustGrow.
Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects”, “is expected”, “budget”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might”, “occur” or “be achieved”.
Forward-looking statements are subject to a number of risks and uncertainties that may cause the actual results of MustGrow to differ materially from those discussed in such forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, MustGrow.
These risks are described in more detail in MustGrow’s Prospectus and other continuous disclosure documents filed by MustGrow with the applicable securities regulatory authorities and available at www.sedar.com. Readers are referred to such documents for more detailed information about MustGrow, which is subject to the qualifications, assumptions and notes set forth therein.
This release does not constitute an offer for sale of, nor a solicitation for offers to buy, any securities in the United States.
Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.